Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Century Therapeutics, Inc
company
About
Century Therapeutics is a leading cell therapy company developing induced pluripotent stem
- 101 - 250
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $250M
- Industries
- Biotechnology,Health Care,Health Diagnostics,Therapeutics
- Founded date
- Jan 1, 2018
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer. The company's genetically-engineered, iPSC-derived immune effector cell products are designed to specifically target hematologic and solid cancers by harnessing the power of adult stem cells, providing patients with an unparalleled opportunity to advance the course of cancer care.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$410M
Century Therapeutics, Inc has raised a total of
$410M
in funding over 2 rounds. Their latest funding was raised on
Mar 3, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 3, 2021 | Series C | $160M | 1 | — | — | Detail |
| Jul 1, 2019 | Series A | $250M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Century Therapeutics, Inc is funded by 1 investors.
Versant Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Versant Ventures
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
